目的观察苦参素与肝动脉插管化疗（TAE）术治疗中晚期肝癌疗效。
Objective: To investigate the effect of Marin solution combined with transcatheter arterial embolization(TAE) on liver cancer .
结论中晚期不能切除的原发性肝癌使用肝动脉、门静脉双重插管灌注化疗，可以改善临床症状、延长存活期。
Conclusion Double intubated hepatic artery and portal vein regional infusion chemotherapy in non-resectable metaphase or late primary liver carcinoma may ameliorate symptoms and prolong survival time.
目的探讨肝动脉、门静脉双重插管区域灌注化疗在中晚期不能切除原发性肝癌应用方法及临床疗效。
Objective To explore the curative effect of double intubated hepatic artery and portal vein regional infusion chemotherapy in non-resectable metaphase or late primary liver carcinoma.
方法对16例不能切除的肝癌采用肝动脉，门静脉同时插管化疗。
Methods From Jan 1996 to Nov 2000, the hepatic artery and portal vein intubation chemotherapy were used in 16 cases with unresectable liver cancer.
方法对146例进展期胃癌病人分组行腹腔热低渗液灌注及动脉插管化疗，并对其腹腔转移率、肝转移率及3年生存率对照研究。
Methods 146 patients were divided into treated and control group. The peritoneal and hepatic recurrence and 3 year survival rate of each group were analyzed.
方法对146例进展期胃癌病人分组行腹腔热低渗液灌注及动脉插管化疗，并对其腹腔转移率、肝转移率及3年生存率对照研究。
Methods 146 patients were divided into treated and control group. The peritoneal and hepatic recurrence and 3 year survival rate of each group were analyzed.
应用推荐